From: Quality of life of patients with ADPKD—Toranomon PKD QOL study: cross-sectional study
I | II | III | IV | V | VI | |
---|---|---|---|---|---|---|
RCS | 0.097 | 0.644 | 0.077 | 0.093 | 0.254 | −0.223 |
Q1 | 0.103 | −0.073 | 0.864 | 0.033 | −0.054 | −0.017 |
Q2 | 0.085 | 0.103 | 0.858 | −0.083 | −0.034 | 0.082 |
Q3 | 0.736 | 0.087 | 0.204 | 0.101 | 0.118 | −0.023 |
Q4 | 0.678 | 0.294 | −0.146 | −0.201 | −0.153 | −0.086 |
Q5 | 0.848 | −0.305 | 0.082 | −0.026 | −0.088 | 0.109 |
Q6 | 0.119 | 0.069 | −0.193 | 0.760 | 0.155 | 0.043 |
Q7 | 0.130 | 0.680 | −0.142 | −0.048 | −0.031 | −0.122 |
Q8 | 0.050 | −0.084 | 0.052 | −0.059 | 0.230 | 0.944 |
Q9 | −0.183 | −0.082 | 0.145 | 0.789 | −0.169 | −0.122 |
Q10 | 0.026 | −0.049 | 0.106 | −0.035 | −0.860 | −0.291 |
Q11 | −0.356 | 0.832 | 0.133 | −0.030 | −0.125 | 0.227 |
Q12 | 0.270 | 0.120 | −0.142 | 0.192 | −0.494 | 0.301 |
pain | −0.403 | −0.328 | −0.131 | −0.074 | −0.043 | −0.053 |
Inter-factor correlations | ||||||
I | - | 0.381 | 0.073 | 0.173 | −0.051 | 0.091 |
II | 0.381 | - | 0.218 | 0.146 | −0.069 | 0.186 |
III | 0.073 | 0.218 | - | 0.101 | 0.020 | −0.112 |
IV | 0.173 | 0.146 | 0.101 | - | −0.098 | 0.084 |
V | −0.051 | −0.069 | 0.020 | −0.098 | - | −0.183 |
VI | 0.091 | 0.186 | −0.112 | 0.084 | −0.183 | - |